Published in Cancer Weekly, February 2nd, 2010
"Disruption of this network may be a mechanism whereby ERalpha-positive breast cancers become resistant to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.